Perifollicular Fibrosis: The Scarring Endgame of Untreated Pattern Loss

Perifollicular fibrosis is the histological finding in advanced AGA that separates recoverable from unrecoverable follicle loss. It is not inevitable in early disease — but is the predictable endgame without adequate treatment.

Androgenetic alopecia is typically presented as a reversible condition — DHT suppression allows miniaturised follicles to recover. This reversibility has a structural limit defined by perifollicular fibrosis: the replacement of the normal perifollicular dermis with dense collagen that progressively compresses and isolates the follicle structure, including its stem cell niche.

Histological findings in AGA scalp

Scalp biopsies from patients with AGA — particularly those with longstanding or advanced disease — consistently show perifollicular fibrosis as a histological finding alongside the expected follicle miniaturisation. The fibrosis appears as concentric bands or sheets of fibrous tissue surrounding miniaturised follicles, replacing the normal loose connective tissue of the perifollicular dermis.

The collagen in these fibrotic bands is dense and organised — mature scar-type collagen (primarily type I) rather than the fine reticular collagen of normal dermis. The distribution follows the miniaturised follicle population, being absent or minimal in non-balding areas of the same scalp.

Mechanism: from miniaturisation to fibrosis

The pathway from DHT-driven miniaturisation to fibrosis involves perifollicular inflammation. AGA-affected scalp shows lymphocytic infiltrates around miniaturised follicle infundibula — a low-grade microinflammatory response that appears to be driven by follicular antigen exposure, microbial dysbiosis (Malassezia), and possibly sebum components. These perifollicular lymphocytes secrete profibrotic cytokines (TGF-beta1, IL-13) that activate resident fibroblasts to produce excess collagen.

The fibrotic tissue progressively compresses the follicle. In late stages, the bulge region — containing the follicle stem cells — is enclosed within fibrotic tissue, mechanically restricting stem cell activation and physically compromising the vascular supply to the papilla. At this stage, follicle recovery with pharmacological DHT suppression alone is limited — the structural damage prevents the papilla from receiving adequate signalling and vascular support even when the DHT stimulus is removed.

Why this justifies early treatment

Perifollicular fibrosis is progressive and cumulative. It develops over years of untreated AGA and advances with each cycle of inflammation and miniaturisation. Early DHT suppression reduces the miniaturisation driving the fibrotic cascade. The follicle that is protected in early AGA does not develop significant perifollicular fibrosis; the follicle lost in untreated AGA over a decade may have irrecoverable fibrotic encasement by the time treatment begins.